Maravai LifeSciences (NASDAQ:MRVI) Raised to “Hold” at UBS Group

Maravai LifeSciences (NASDAQ:MRVI) was upgraded by equities researchers at UBS Group to a “hold” rating in a research report issued on Wednesday, Zacks reports.

Several other research analysts also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. Wells Fargo & Company lifted their target price on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Wall Street Zen lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences has a consensus rating of “Hold” and a consensus price target of $6.83.

Maravai LifeSciences Price Performance

NASDAQ:MRVI opened at $6.53 on Wednesday. Maravai LifeSciences has a 12 month low of $2.55 and a 12 month high of $9.42. The stock has a 50 day moving average of $6.86 and a two-hundred day moving average of $5.05. The company has a current ratio of 4.05, a quick ratio of 2.98 and a debt-to-equity ratio of 0.49. The firm has a market cap of $1.70 billion, a P/E ratio of -12.56 and a beta of 0.60.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. The business had revenue of $51.44 million during the quarter, compared to analysts’ expectations of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. On average, analysts expect that Maravai LifeSciences will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MRVI. California State Teachers Retirement System grew its position in shares of Maravai LifeSciences by 61.5% in the second quarter. California State Teachers Retirement System now owns 9,553 shares of the company’s stock valued at $60,000 after purchasing an additional 3,639 shares in the last quarter. Royal Bank of Canada lifted its position in Maravai LifeSciences by 49.0% during the first quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after buying an additional 3,209 shares in the last quarter. Virtu Financial LLC acquired a new position in Maravai LifeSciences during the fourth quarter worth $34,000. Insigneo Advisory Services LLC acquired a new position in Maravai LifeSciences during the fourth quarter worth $34,000. Finally, Quantessence Capital LLC purchased a new stake in Maravai LifeSciences in the 3rd quarter valued at $31,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.